

Product News

Lonza Group Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
www.lonza.com

Fight against the H1N1 Virus with Lonza Formulations

Basel, Switzerland, 01 October 2009 – The recent global outbreak of H1N1 influenza has highlighted the importance of proper hygiene, including the cleaning and disinfecting of hard surfaces.

The United States Environmental Protection Agency (EPA), responsible for the biocide products efficacy and safety in the U.S., has recently stated that those products currently registered for use against Influenza type A virus will also be effective against the 2009-H1N1 (swine) flu strain.

Lonza offers six formulations effective against Influenza A virus (H1N1).

The following Lonza formulations are tested against Influenza A virus (H1N1) according to test design EN 14476:2005:

Lonzagard™ DM 114-10

Dirty conditions, 3.0%, 15 minute contact time

Lonzagard™ DR 15

Dirty conditions, 1.0%, 15 minute contact time

Lonzagard™ DR-19a

Dirty conditions, 1.0%, 15 minute contact time

Lonzagard™ DR-25a

Dirty conditions, 0.5%, 15 minute contact time

Lonzagard™ DR-25aN:

Dirty conditions, 0.5%, 15 minute contact time

Lonzagard™ MC-A 30

Dirty conditions, 1.0%, 15 minute contact time

For safe and effective use of these products, all label instructions have to be carefully applied. Also remember that your first line of defense is the frequent and thorough washing of hands with soap and water. Disinfectant type products are not for use on skin and should only be used on hard, non-porous surfaces.

For further information, please contact our specialists: hygiene@lonza.com

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically.

Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.

For further information

Lonza Group Ltd
Head Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624
michael.frizberg@lonza.com

Lonza Group Ltd
Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Marcel Rosenast
Tel +41 61 316 8728
Fax +41 61 316 9728
marcel.rosenast@lonza.com